Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Hervas-Stubbs, S. (Sandra) | - |
dc.creator | Lasarte, J.J. (Juan José) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.creator | Cullen, J.M. (John M.) | - |
dc.creator | Roggendorf, M. (Michael) | - |
dc.creator | Borras-Cuesta, F. (Francisco) | - |
dc.date.accessioned | 2012-04-04T09:43:58Z | - |
dc.date.available | 2012-04-04T09:43:58Z | - |
dc.date.issued | 1997 | - |
dc.identifier.citation | Hervas-Stubbs S, Lasarte JJ, Sarobe P, Prieto J, Cullen J, Roggendorf M, et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 1997 Oct;27(4):726-737. | es_ES |
dc.identifier.issn | 1600-0641 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21597 | - |
dc.description.abstract | BACKGROUND/AIMS: Therapeutic vaccination is a new approach to treat patients with chronic hepatitis B virus infection. We have used the woodchuck model to examine the efficacy and safety of this approach. METHODS: Seven woodchucks chronically infected with woodchuck hepatitis virus were immunized with surface antigen from this virus, purified from plasma, in conjunction with a peptide named FIS (encompassing amino acids 106-118: FISEAIIHVLHSR from sperm whale myoglobin), which is recognized by T helper lymphocytes. As controls, two woodchucks chronically infected with woodchuck hepatitis virus were immunized: one with FIS only and the other with surface antigen only. RESULTS: Co-immunization with surface antigen and FIS, but not with FIS or surface antigen alone, induced anti-surface antibodies in 7/7 immunized woodchucks. In the two woodchucks in which the highest titer of anti-surface antibody was elicited, severe liver damage was observed: one died of fulminant hepatitis and the other became seriously ill with hepatic injury and had to be sacrificed. CONCLUSIONS: Co-immunization of chronically infected woodchucks with surface antigen and a peptide recognized by T helper cells produces a good anti-surface antibody response. However, this strategy needs to be optimized before its implementation in humans. Although our experiments are not strictly comparable to vaccination of chronically hepatitis B virus-infected patients with recombinant or plasma-derived vaccines, we believe that precautions should be taken to avoid the risk of severe liver injury when immunizing hepatitis B virus carriers. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Antibodies | es_ES |
dc.subject | Hepatitis | es_ES |
dc.subject | Immune therapy | es_ES |
dc.subject | Peptides | es_ES |
dc.subject | T-cell help | es_ES |
dc.subject | Vaccination | es_ES |
dc.subject | Woodchuck | es_ES |
dc.subject | Woodchuck hepatitis virus (WHV) | es_ES |
dc.subject | Woodchuck hepatitis virus surface antigen (WHsAg) | es_ES |
dc.title | Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://www.sciencedirect.com/science/article/pii/S0168827897800906 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.